Research programme: curcumin analogues - Traverse Biosciences

Drug Profile

Research programme: curcumin analogues - Traverse Biosciences

Alternative Names: CMC 2.24; TRB N0224

Latest Information Update: 20 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator State University of New York at Stony Brook
  • Developer The Feinstein Institute for Medical Research; Traverse Biosciences
  • Class Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroblastoma
  • Research Osteoarthritis

Most Recent Events

  • 20 Apr 2016 Preclinical trials in Neuroblastoma in USA (PO) prior to April 2016
  • 20 Apr 2016 Pharmacodynamics data from a preclinical trial in Neuroblastoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 29 Jul 2014 Early research in Osteoarthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top